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et al., 2012). Additional drugs, acting through other mechanisms 
of action, are now in clinical development (e.g., vascular targeted 
NGR-tumor necrosis factor, in phase II/III studies) (Sacchi et al., 
2006) and others are about to enter clinical investigation (e.g., 
Junction Opener-1) (Beyer et al., 2011, 2012).
To date, the focus has been primarily on the identification of 
novel promoter drugs that improve tumor drug delivery. This has 
led to a considerable number of promoter drugs and devices that are 
effective in preclinical studies, and some of which have proceeded 
into clinical investigation or are about to do so. Regarding the types 
of drugs to be delivered, chemotherapeutics have been the obvious 
first choice, because they are the antitumor drugs in most wide-
spread use (Curnis et al., 2002; Beyer et al., 2012). Another area of 
interest is antitumor monoclonal antibodies or related compounds 
(e.g., immunocytokines) (Beyer et al., 2011; Moschetta et al., 2012), 
which have become an important component of the antitumor 
drug armamentarium over the last 15 years. Preclinical investi-
gations have produced promising results when these therapeutic 
agents are combined with drugs that enhance their penetration 
into tumors, and it is reasonable to predict that clinical studies will 
follow in the forthcoming years. So far, so good, but what next? 
Have we looked at all possible applications for promoter drugs, 
or are there further applications that we can envisage? We believe 
that there is still an important field of application for promoter 
drugs that has been relatively unexplored so far, i.e., the possibil-
ity to improve delivery of anticancer cells, in particular immune 
cells to the tumor (Marcucci et al., 2013), an area of increasing 
clinical interest.
Enhancing penetration of immune cells into tumors may have 
two main therapeutic applications. The first is to improve the effi-
cacy of immune-regulatory antibodies, such as the anti-cytotoxic 
T-lymphocyte antigen-4 antibody ipilimumab, and the anti-
programed death-1 antibody nivolumab. These antibodies yield 
impressive, and often long-lasting therapeutic responses in a limited 
fraction (10–20% depending on the antibody) of heavily pretreated 
patients with metastatic melanoma and other solid tumors (Hodi 
et al., 2010; Topalian et al., 2012). There is a relationship between 
the number of tumor-infiltrating immune cells and responsiveness 
to ipilimumab (Lynch et al., 2012). In this setting, promoter drugs 
could be of value at two levels: first, to improve tumor delivery of 
the antibody itself, and second, improve penetration of immune 
cells into the tumor. This has the potential to increase the fraction 
of patients that become responders to these  antibodies. A second 
The main scope of this topic is to give an update on approaches 
being studied and developed to improve tumor drug delivery 
through active targeting and other methods. Inadequate drug 
accumulation has emerged as one of the main problems under-
lying therapeutic failure and drug resistance in the treatment of 
solid tumors (Trédan et al., 2007; Marcucci and Corti, 2012a). It is 
causally related to the abnormal tumor architecture. Poor vascu-
larization, increased resistance to blood flow and impaired blood 
supply represent a first obstacle to the delivery of antitumor drugs 
to tumor cells. Decreased or even inverted transvascular pressure 
gradients compromise convective transport of drugs. Eventually, an 
abnormal extracellular matrix offers increased frictional resistance 
to tumor drug penetration. The net result is reduced overall drug 
accumulation in tumors, and the propensity of drugs to accumulate 
in perivascular spaces without penetrating vessel-distant tumor 
areas. This promotes passive and active induction of drug resistance 
(Marcucci and Corti, 2012b).
Abnormal tumor architecture, inadequate drug accumulation 
and tumor drug resistance are tightly linked phenomena, suggest-
ing that normalization of the tumor architecture, including tumor 
blood vessels, may result in increased drug delivery to tumors and 
improve the therapeutic efficacy of anticancer drugs. Indeed, sev-
eral classes of drugs, that we have referred to as promoter drugs, 
(Marcucci and Corti, 2012a) have been reported to increase tumor 
uptake and penetration of antitumor drugs, including drugs that 
are: (1) vasoactive (Nagamitsu et al., 2009), (2) normalize tumor 
vessels (Jain, 2005), (3) modify the barrier function of tumor 
vessels (Corti and Marcucci, 1998; Curnis et al., 2000, 2002), (4) 
debulk tumor cells (Padera et al., 2004; Moschetta et al., 2012), 
(5) overcome intercellular (Beyer et al., 2011, 2012; Wang et al., 
2011) and stromal barriers (Provenzano et al., 2012). In addition, 
non-pharmacologic approaches have been described that enhance 
tumor accumulation of effector drugs (e.g., convection-enhanced 
delivery, hyperthermia, ultrasound, etc.) (Sen et al., 2011; Watson 
et al., 2012).
Some drugs that have already received regulatory approval (e.g., 
the anti-vascular endothelial growth factor antibody bevacizumab) 
(Hurwitz et al., 2004) exert antitumor effects at least in part by nor-
malizing the tumor vasculature and enhancing tumor accumula-
tion of chemotherapeutic drugs (Willett et al., 2004). Bevacizumab, 
however, has a problematic side-effect profile, and the effective 
doses of the drug encompass a very narrow range beyond which 
it may even lead to a reduction in drug delivery (Van der Veldt 
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possible field of application are antitumor vaccines. Antitumor 
vaccines are often active only when administered in a prophylactic 
setting. With growing tumors, vaccination becomes progressively 
less effective. One reason might be that tumor-specific lymphocytes 
become sensitized in draining lymph nodes but are then unable 
to enter tumors and eliminate tumor cells (Ganss and Hanahan, 
1998). Promoter drugs that improve infiltration of immune cells 
into tumors may prove useful in increasing the effectiveness of 
cancer vaccines. However, infiltration of immune cells into tumors 
has requirements that go beyond those of antitumor drugs. 
Physiological pathways of immune cell extravasation depend on a 
multistep cascade of events involving tethering, rolling, firm adhe-
sion, and migration. These steps are mediated by distinct adhe-
sion molecules and activation pathways (Springer, 1994); however, 
adhesion molecules are often downregulated on tumor endothelial 
cells, a phenomenon defined as endothelial cell anergy (Piali et al., 
1995). This impairs the entry of immune cells into tumor sites. In 
order to enhance tumor infiltration of immune cells, promoter 
drugs may be required that induce a local  inflammatory reaction. 
This leads to up-regulation of adhesion receptors that are able to 
attach immune cells to vessel walls and enable their penetration into 
tumors. Preliminary studies suggest that certain promoter drugs 
may achieve this goal (Calcinotto et al., 2012).
Promoter drugs that improve tumor delivery of chemotherapeu-
tics and antitumor antibodies are likely to become a clinical reality 
in forthcoming years. In addition, new possibilities are emerging to 
enhance the entrance of therapeutic agents into tumors. For exam-
ple, recent results suggest that promoter drugs may be useful also 
for improving infiltration of immune cells into tumors. This may 
increase the antitumor effects of a broad range of immune-based 
therapeutics, including immune-regulatory antibodies, antibodies 
that engage cytotoxic immune cells, and cancer vaccines.
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